Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance
Asthma drugs reprogram tumor-fighting immune cells and overcome resistance to checkpoint therapy in mice, warranting rapid clinical translation.
CysLTR1 — a receptor known in asthma — is induced by STAT3 in tumors to sustain immunosuppressive myelopoiesis; its inhibition with clinically available antagonists reprograms neutrophils to an antitumor phenotype and overcomes anti-PD1 resistance in multiple mouse models. Published in Nature Cancer, this work nominates existing CysLTR1 antagonists (used in asthma) for rapid translation as checkpoint resistance-reversing agents, though all data are currently preclinical.
What the study was
- Study design
- Preclinical: genetic ablation + pharmacological inhibition in multiple mouse tumor models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nat Cancer
Why it surfaced
Nat Cancer preclinical study with high translational promise: clinically available CysLTR1 antagonists could be repurposed to overcome checkpoint resistance. Score capped at 5 (non-human). High watch priority for Phase I trial announcement.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.